{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:49:18Z","timestamp":1790192958875,"version":"4.1.0"},"reference-count":137,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Taube Philanthropies"},{"DOI":"10.13039\/100001212","name":"Koret Foundation","doi-asserted-by":"publisher","award":["12-0160"],"award-info":[{"award-number":["12-0160"]}],"id":[{"id":"10.13039\/100001212","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008918","name":"Jean Perkins Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008918","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Wilma Marvelle Jones Research Fund"},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01 AG061120-01"],"award-info":[{"award-number":["R01 AG061120-01"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s13311-021-01023-8","type":"journal-article","created":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T17:02:21Z","timestamp":1617123741000},"page":"1039-1063","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Neuroimaging, Urinary, and Plasma Biomarkers of Treatment Response in Huntington's Disease: Preclinical Evidence with the p75NTR Ligand LM11A-31"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6122-840X","authenticated-orcid":false,"given":"Danielle A.","family":"Simmons","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian D.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert R.","family":"Butler III","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Kuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyne L.M.","family":"McHugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Akers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wassim","family":"Syriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maged","family":"Grouban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Zeineh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank M.","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-021-01023-8_bib1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes","volume":"72","author":"Group HsDCR","year":"1993","journal-title":"Cell"},{"key":"10.1007\/s13311-021-01023-8_bib2","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00005072-199805000-00001","article-title":"Huntington disease","volume":"57","author":"Vonsattel","year":"1998","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1007\/s13311-021-01023-8_bib3","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","article-title":"Neuropathological classification of Huntington's disease","volume":"44","author":"Vonsattel","year":"1985","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1007\/s13311-021-01023-8_bib4","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1212\/01.WNL.0000065888.88988.6E","article-title":"Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis","volume":"60","author":"Rosas","year":"2003","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01023-8_bib5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3233\/JHD-170275","article-title":"Modulating neurotrophin receptor signaling as a therapeutic strategy for Huntington's disease","volume":"6","author":"Simmons","year":"2017","journal-title":"J Huntingtons Dis"},{"key":"10.1007\/s13311-021-01023-8_bib6","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.neuron.2014.05.032","article-title":"Impaired TrkB receptor signaling underlies corticostriatal dysfunction in Huntington's disease","volume":"83","author":"Plotkin","year":"2014","journal-title":"Neuron"},{"key":"10.1007\/s13311-021-01023-8_bib7","doi-asserted-by":"crossref","first-page":"4411","DOI":"10.1172\/JCI74809","article-title":"Neurotrophin receptor p75(NTR) mediates Huntington's disease-associated synaptic and memory dysfunction","volume":"124","author":"Brito","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-021-01023-8_bib8","first-page":"4920","article-title":"A small molecule p75NTR ligand normalizes signalling and reduces Huntington's disease phenotypes in R6\/2 and BACHD mice","volume":"25","author":"Simmons","year":"2016","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-021-01023-8_bib9","doi-asserted-by":"crossref","unstructured":"Miguez A, Garcia-Diaz Barriga G, Brito V, et al. Fingolimod (FTY720) enhances hippocampal synaptic plasticity and memory in Huntington's disease by preventing p75NTR up-regulation and astrocyte-mediated inflammation. Hum Mol Genet 2015.","DOI":"10.1093\/hmg\/ddv218"},{"key":"10.1007\/s13311-021-01023-8_bib10","doi-asserted-by":"crossref","first-page":"e595","DOI":"10.1038\/cddis.2013.116","article-title":"Imbalance of p75(NTR)\/TrkB protein expression in Huntington's disease: implication for neuroprotective therapies","volume":"4","author":"Brito","year":"2013","journal-title":"Cell Death Dis"},{"key":"10.1007\/s13311-021-01023-8_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102136","article-title":"A small molecule p75NTR ligand, LM11A-31, reverses cholinergic neurite dystrophy in Alzheimer's disease mouse models with mid- to late-stage disease progression","volume":"9","author":"Simmons","year":"2014","journal-title":"PLoS One"},{"key":"10.1007\/s13311-021-01023-8_bib12","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2174\/1871527315666161107093047","article-title":"Neurotrophin receptor signaling as a therapeutic target for Huntington's disease","volume":"16","author":"Simmons","year":"2017","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1007\/s13311-021-01023-8_bib13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1750-3639.2007.00111.x","article-title":"Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington's disease","volume":"18","author":"Zuccato","year":"2008","journal-title":"Brain Pathol"},{"key":"10.1007\/s13311-021-01023-8_bib14","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1523\/JNEUROSCI.3547-05.2006","article-title":"Small, nonpeptide p75NTR ligands induce survival signaling and inhibit proNGF-induced death","volume":"26","author":"Massa","year":"2006","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-021-01023-8_bib15","doi-asserted-by":"crossref","first-page":"e3604","DOI":"10.1371\/journal.pone.0003604","article-title":"Small molecule, non-peptide p75 ligands inhibit Abeta-induced neurodegeneration and synaptic impairment","volume":"3","author":"Yang","year":"2008","journal-title":"PLoS One"},{"key":"10.1007\/s13311-021-01023-8_bib16","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/hmg\/ddy202","article-title":"TSPO-PET imaging using [18F]PBR06 is a potential translatable biomarker for treatment response in Huntington's disease: preclinical evidence with the p75NTR ligand LM11A-31","volume":"27","author":"Simmons","year":"2018","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-021-01023-8_bib17","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2174\/1573405614666181115113400","article-title":"Diffusion tensor imaging in preclinical and human studies of Huntington's disease: what have we learned so far?","volume":"15","author":"Gatto","year":"2019","journal-title":"Curr Med Imaging Rev"},{"key":"10.1007\/s13311-021-01023-8_bib18","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/bs.irn.2018.09.006","article-title":"Structural magnetic resonance imaging in Huntington's disease","volume":"142","author":"Wilson","year":"2018","journal-title":"Int Rev Neurobiol"},{"key":"10.1007\/s13311-021-01023-8_bib19","doi-asserted-by":"crossref","unstructured":"Zeun P, Scahill RI, Tabrizi SJ, Wild EJ. Fluid and imaging biomarkers for Huntington's disease. Mol Cell Neurosci 2019.","DOI":"10.1016\/j.mcn.2019.02.004"},{"key":"10.1007\/s13311-021-01023-8_bib20","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.neuroimage.2010.04.273","article-title":"Evaluating imaging biomarkers for neurodegeneration in pre-symptomatic Huntington's disease using machine learning techniques","volume":"56","author":"Rizk-Jackson","year":"2011","journal-title":"Neuroimage"},{"key":"10.1007\/s13311-021-01023-8_bib21","doi-asserted-by":"crossref","first-page":"e87398","DOI":"10.1371\/journal.pone.0087398","article-title":"The extracellular domain of neurotrophin receptor p75 as a candidate biomarker for amyotrophic lateral sclerosis","volume":"9","author":"Shepheard","year":"2014","journal-title":"PLoS One"},{"key":"10.1007\/s13311-021-01023-8_bib22","doi-asserted-by":"crossref","first-page":"e650","DOI":"10.1038\/tp.2015.146","article-title":"Differential levels of p75NTR ectodomain in CSF and blood in patients with Alzheimer's disease: a novel diagnostic marker","volume":"5","author":"Jiao","year":"2015","journal-title":"Transl Psychiatry"},{"key":"10.1007\/s13311-021-01023-8_bib23","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell"},{"key":"10.1007\/s13311-021-01023-8_bib24","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1073\/pnas.1221891110","article-title":"Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease","volume":"110","author":"Sathasivam","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-021-01023-8_bib25","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.nbd.2009.05.007","article-title":"Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models","volume":"35","author":"Menalled","year":"2009","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-021-01023-8_bib26","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/glia.20526","article-title":"Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease","volume":"55","author":"Simmons","year":"2007","journal-title":"Glia"},{"key":"10.1007\/s13311-021-01023-8_bib27","doi-asserted-by":"crossref","first-page":"18712","DOI":"10.1523\/JNEUROSCI.1310-13.2013","article-title":"A small molecule TrkB ligand reduces motor impairment and neuropathology in R6\/2 and BACHD mouse models of Huntington's disease","volume":"33","author":"Simmons","year":"2013","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-021-01023-8_bib28","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrd4024","article-title":"Small-molecule modulation of neurotrophin receptors: a strategy for the treatment of neurological disease","volume":"12","author":"Longo","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1007\/s13311-021-01023-8_bib29","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/j.neurobiolaging.2013.02.015","article-title":"A small molecule p75NTR ligand prevents cognitive deficits and neurite degeneration in an Alzheimer's mouse model","volume":"34","author":"Knowles","year":"2013","journal-title":"Neurobiol Aging"},{"key":"10.1007\/s13311-021-01023-8_bib30","doi-asserted-by":"crossref","first-page":"10627","DOI":"10.1523\/JNEUROSCI.0620-09.2009","article-title":"The p75 neurotrophin receptor promotes amyloid-beta(1\u201342)-induced neuritic dystrophy in vitro and in vivo","volume":"29","author":"Knowles","year":"2009","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-021-01023-8_bib31","first-page":"1","article-title":"Advanced normalization tools (ANTS)","volume":"2","author":"Avants","year":"2009","journal-title":"Insight J"},{"issue":"Suppl 1","key":"10.1007\/s13311-021-01023-8_bib32","doi-asserted-by":"crossref","first-page":"S208","DOI":"10.1016\/j.neuroimage.2004.07.051","article-title":"Advances in functional and structural MR image analysis and implementation as FSL","volume":"23","author":"Smith","year":"2004","journal-title":"Neuroimage"},{"key":"10.1007\/s13311-021-01023-8_bib33","doi-asserted-by":"crossref","first-page":"S173","DOI":"10.1016\/j.neuroimage.2008.10.055","article-title":"Bayesian analysis of neuroimaging data in FSL","volume":"45","author":"Woolrich","year":"2009","journal-title":"Neuroimage"},{"key":"10.1007\/s13311-021-01023-8_bib34","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.neuroimage.2006.01.015","article-title":"User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability","volume":"31","author":"Yushkevich","year":"2006","journal-title":"Neuroimage"},{"key":"10.1007\/s13311-021-01023-8_bib35","doi-asserted-by":"crossref","first-page":"6456","DOI":"10.1523\/JNEUROSCI.0388-12.2012","article-title":"R6\/2 Huntington's disease mice develop early and progressive abnormal brain metabolism and seizures","volume":"32","author":"Cepeda-Prado","year":"2012","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-021-01023-8_bib36","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.nbd.2008.09.017","article-title":"Use of magnetic resonance imaging for anatomical phenotyping of the R6\/2 mouse model of Huntington's disease","volume":"33","author":"Sawiak","year":"2009","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-021-01023-8_bib37","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3233\/JHD-160208","article-title":"Similar progression of morphological and metabolic phenotype in R6\/2 mice with different CAG repeats revealed by in vivo magnetic resonance imaging and spectroscopy","volume":"5","author":"Sawiak","year":"2016","journal-title":"J Huntingtons Dis"},{"key":"10.1007\/s13311-021-01023-8_bib38","doi-asserted-by":"crossref","first-page":"e84726","DOI":"10.1371\/journal.pone.0084726","article-title":"Correlations of behavioral deficits with brain pathology assessed through longitudinal MRI and histopathology in the R6\/1 mouse model of Huntington's disease","volume":"8","author":"Rattray","year":"2013","journal-title":"PLoS One"},{"key":"10.1007\/s13311-021-01023-8_bib39","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1093\/hmg\/ddy119","article-title":"A whole brain longitudinal study in the YAC128 mouse model of Huntington's disease shows distinct trajectories of neurochemical, structural connectivity and volumetric changes","volume":"27","author":"Petrella","year":"2018","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-021-01023-8_bib40","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(11)70263-0","article-title":"Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data","volume":"11","author":"Tabrizi","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-021-01023-8_bib41","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.neuroimage.2012.03.072","article-title":"NODDI: practical in vivo neurite orientation dispersion and density imaging of the human brain","volume":"61","author":"Zhang","year":"2012","journal-title":"Neuroimage"},{"key":"10.1007\/s13311-021-01023-8_bib42","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/biomet\/93.3.491","article-title":"Adaptive linear set-up procedures that control the false discovery rate","volume":"93","author":"Benjamini","year":"2006","journal-title":"Biometrika"},{"key":"10.1007\/s13311-021-01023-8_bib43","first-page":"2825","article-title":"Scikit-learn: machine learning in {P}ython","volume":"12","author":"Pedregosa","year":"2011","journal-title":"Journal of Machine Learning Research"},{"key":"10.1007\/s13311-021-01023-8_bib44","doi-asserted-by":"crossref","first-page":"12","DOI":"10.11613\/BM.2014.003","volume":"24","author":"Sperandei","year":"2014","journal-title":"Understanding logistic regression analysis. Biochem Med (Zagreb)"},{"key":"10.1007\/s13311-021-01023-8_bib45","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/00031305.1992.10475879","article-title":"An introduction to kernel and nearest-neighbor nonparametric regression","volume":"46","author":"Altman","year":"1992","journal-title":"The American Statistician"},{"key":"10.1007\/s13311-021-01023-8_bib46","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1023\/A:1010933404324","article-title":"Random forests","volume":"45","author":"Breiman","year":"2001","journal-title":"Machine Learning"},{"key":"10.1007\/s13311-021-01023-8_bib47","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.neubiorev.2012.01.004","article-title":"Using support vector machine to identify imaging biomarkers of neurological and psychiatric disease: a critical review","volume":"36","author":"Orru","year":"2012","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1007\/s13311-021-01023-8_bib48","doi-asserted-by":"crossref","unstructured":"Chen T, Guestrin C. XGBoost: a scalable tree boosting system. Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining: 2016 2016;San Francisco, CA: ACM (2016):785-794.","DOI":"10.1145\/2939672.2939785"},{"key":"10.1007\/s13311-021-01023-8_bib49","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1016\/j.neuroimage.2009.10.027","article-title":"Longitudinal characterization of brain atrophy of a Huntington's disease mouse model by automated morphological analyses of magnetic resonance images","volume":"49","author":"Zhang","year":"2010","journal-title":"Neuroimage"},{"key":"10.1007\/s13311-021-01023-8_bib50","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.pscychresns.2011.01.007","article-title":"Statistical adjustments for brain size in volumetric neuroimaging studies: some practical implications in methods","volume":"193","author":"O'Brien","year":"2011","journal-title":"Psychiatry Res"},{"key":"10.1007\/s13311-021-01023-8_bib51","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/mds.20979","article-title":"Diffusion tensor imaging in presymptomatic and early Huntington's disease: selective white matter pathology and its relationship to clinical measures","volume":"21","author":"Rosas","year":"2006","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-021-01023-8_bib52","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/ana.25309","article-title":"In vivo characterization of white matter pathology in premanifest Huntington's disease","volume":"84","author":"Zhang","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-021-01023-8_bib53","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.parkreldis.2016.09.005","article-title":"Diffusion imaging studies of Huntington's disease: a meta-analysis","volume":"32","author":"Liu","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1007\/s13311-021-01023-8_bib54","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.neubiorev.2013.01.022","article-title":"Structural MRI in Huntington's disease and recommendations for its potential use in clinical trials","volume":"37","author":"Georgiou-Karistianis","year":"2013","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1007\/s13311-021-01023-8_bib55","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/hbm.22019","article-title":"Seeking Huntington disease biomarkers by multimodal, cross-sectional basal ganglia imaging","volume":"34","author":"Sanchez-Castaneda","year":"2013","journal-title":"Hum Brain Mapp"},{"key":"10.1007\/s13311-021-01023-8_bib56","doi-asserted-by":"crossref","first-page":"720","DOI":"10.3389\/fnins.2017.00720","article-title":"NODDI-DTI: estimating neurite orientation and dispersion parameters from a diffusion tensor in healthy white matter","volume":"11","author":"Edwards","year":"2017","journal-title":"Front Neurosci"},{"key":"10.1007\/s13311-021-01023-8_bib57","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/hbm.22612","article-title":"The role of iron in gray matter degeneration in Huntington's disease: a magnetic resonance imaging study","volume":"36","author":"Sanchez-Castaneda","year":"2015","journal-title":"Hum Brain Mapp"},{"key":"10.1007\/s13311-021-01023-8_bib58","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1001\/archneur.56.5.569","article-title":"Increased basal ganglia iron levels in Huntington disease","volume":"56","author":"Bartzokis","year":"1999","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-021-01023-8_bib59","unstructured":"Bartzokis G, Tishler T. MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntingon's disease. Cell Mol Biol (Noisy-le-grand) 2000;46:821-833."},{"key":"10.1007\/s13311-021-01023-8_bib60","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/archneurol.2011.2945","article-title":"Alterations in brain transition metals in Huntington disease: an evolving and intricate story","volume":"69","author":"Rosas","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-021-01023-8_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0118907","article-title":"Correlation between relaxometry and diffusion tensor imaging in the globus pallidus of Huntington's disease patients","volume":"10","author":"Syka","year":"2015","journal-title":"PLoS One"},{"key":"10.1007\/s13311-021-01023-8_bib62","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3174\/ajnr.A4617","article-title":"Quantitative susceptibility mapping suggests altered brain iron in premanifest Huntington disease","volume":"37","author":"van Bergen","year":"2016","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1007\/s13311-021-01023-8_bib63","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/jnnp-2014-310183","article-title":"Iron accumulation in the basal ganglia in Huntington's disease: cross-sectional data from the IMAGE-HD study","volume":"87","author":"Dominguez","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-021-01023-8_bib64","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/jnr.24358","article-title":"Altered brain iron content and deposition rate in Huntington's disease as indicated by quantitative susceptibility MRI","volume":"97","author":"Chen","year":"2019","journal-title":"J Neurosci Res"},{"key":"10.1007\/s13311-021-01023-8_bib65","doi-asserted-by":"crossref","unstructured":"Jurgens CK, Jasinschi R, Ekin A, et al. MRI T2 Hypointensities in basal ganglia of premanifest Huntington's disease. PLoS Curr 2010;2.","DOI":"10.1371\/currents.RRN1173"},{"key":"10.1007\/s13311-021-01023-8_bib66","doi-asserted-by":"crossref","unstructured":"Gelman N, Ewing JR, Gorell JM, Spickler EM, Solomon EG. Interregional variation of longitudinal relaxation rates in human brain at 3.0 T: relation to estimated iron and water contents. Magn Reson Med 2001;45:71-79.","DOI":"10.1002\/1522-2594(200101)45:1<71::AID-MRM1011>3.0.CO;2-2"},{"key":"10.1007\/s13311-021-01023-8_bib67","first-page":"1593","article-title":"Quantitative susceptibility mapping (QSM) as a means to measure brain iron?","volume":"62","author":"Langkammer","year":"2012","journal-title":"A post mortem validation study. Neuroimage"},{"key":"10.1007\/s13311-021-01023-8_bib68","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.neuroimage.2018.04.047","article-title":"Quantifying iron content in magnetic resonance imaging","volume":"187","author":"Ghassaban","year":"2019","journal-title":"Neuroimage"},{"key":"10.1007\/s13311-021-01023-8_bib69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147947","article-title":"Magnetic resonance imaging features of the nigrostriatal system: biomarkers of Parkinson's disease stages?","volume":"11","author":"Hopes","year":"2016","journal-title":"PLoS One"},{"key":"10.1007\/s13311-021-01023-8_bib70","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.neuroimage.2015.12.045","article-title":"Accumulation of iron in the putamen predicts its shrinkage in healthy older adults: a multi-occasion longitudinal study","volume":"128","author":"Daugherty","year":"2016","journal-title":"Neuroimage"},{"key":"10.1007\/s13311-021-01023-8_bib71","doi-asserted-by":"crossref","first-page":"116544","DOI":"10.1016\/j.neuroimage.2020.116544","article-title":"Striatal iron content is linked to reduced fronto-striatal brain function under working memory load","volume":"210","author":"Rodrigue","year":"2020","journal-title":"Neuroimage"},{"key":"10.1007\/s13311-021-01023-8_bib72","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.neuroimage.2014.09.044","article-title":"Disentangling in vivo the effects of iron content and atrophy on the ageing human brain","volume":"103","author":"Lorio","year":"2014","journal-title":"Neuroimage"},{"key":"10.1007\/s13311-021-01023-8_bib73","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1159\/000147312","article-title":"Histochemical distribution of non-haem iron in the human brain","volume":"144","author":"Morris","year":"1992","journal-title":"Acta Anat (Basel)"},{"key":"10.1007\/s13311-021-01023-8_bib74","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1471-4159.1992.tb08904.x","article-title":"Uptake and distribution of iron and transferrin in the adult rat brain","volume":"59","author":"Morris","year":"1992","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-021-01023-8_bib75","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.3174\/ajnr.A3932","article-title":"Quantitative 7T phase imaging in premanifest Huntington disease","volume":"35","author":"Apple","year":"2014","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1007\/s13311-021-01023-8_bib76","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.neuroimage.2012.03.056","article-title":"Elevated brain iron is independent from atrophy in Huntington's disease","volume":"61","author":"Dumas","year":"2012","journal-title":"Neuroimage"},{"key":"10.1007\/s13311-021-01023-8_bib77","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/jnc.12739","article-title":"Iron dysregulation in Huntington's disease","volume":"130","author":"Muller","year":"2014","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-021-01023-8_bib78","doi-asserted-by":"crossref","first-page":"e77023","DOI":"10.1371\/journal.pone.0077023","article-title":"Iron accumulates in Huntington's disease neurons: protection by deferoxamine","volume":"8","author":"Chen","year":"2013","journal-title":"PLoS One"},{"key":"10.1007\/s13311-021-01023-8_bib79","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00702-010-0430-7","article-title":"Neuroinflammation in Huntington's disease","volume":"117","author":"Moller","year":"2010","journal-title":"J Neural Transm"},{"key":"10.1007\/s13311-021-01023-8_bib80","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/glia.10161","article-title":"Microglia as a source and target of cytokines","volume":"40","author":"Hanisch","year":"2002","journal-title":"Glia"},{"key":"10.1007\/s13311-021-01023-8_bib81","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1084\/jem.20080178","article-title":"A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease","volume":"205","author":"Bjorkqvist","year":"2008","journal-title":"J Exp Med"},{"key":"10.1007\/s13311-021-01023-8_bib82","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1179\/1743132812Y.0000000073","article-title":"Oxidative stress and inflammation biomarkers in the blood of patients with Huntington's disease","volume":"34","author":"Sanchez-Lopez","year":"2012","journal-title":"Neurol Res"},{"key":"10.1007\/s13311-021-01023-8_bib83","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.euroneuro.2014.05.004","article-title":"Acute-phase proteins in relation to neuropsychiatric symptoms and use of psychotropic medication in Huntington's disease","volume":"24","author":"Bouwens","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1007\/s13311-021-01023-8_bib84","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.bbi.2014.09.011","article-title":"Plasma inflammatory biomarkers for Huntington's disease patients and mouse model","volume":"44","author":"Chang","year":"2015","journal-title":"Brain Behav Immun"},{"key":"10.1007\/s13311-021-01023-8_bib85","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1021\/pr0700753","article-title":"Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates","volume":"6","author":"Dalrymple","year":"2007","journal-title":"J Proteome Res"},{"key":"10.1007\/s13311-021-01023-8_bib86","doi-asserted-by":"crossref","first-page":"20358","DOI":"10.1074\/jbc.M109.082834","article-title":"p75 neurotrophin receptor-mediated apoptosis in sympathetic neurons involves a biphasic activation of JNK and up-regulation of tumor necrosis factor-alpha-converting enzyme\/ADAM17","volume":"285","author":"Kenchappa","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-021-01023-8_bib87","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1212\/WNL.0000000000003741","article-title":"Urinary p75(ECD): A prognostic, disease progression, and pharmacodynamic biomarker in ALS","volume":"88","author":"Shepheard","year":"2017","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01023-8_bib88","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1212\/01.wnl.0000341768.28646.b6","article-title":"Automatic detection of preclinical neurodegeneration: presymptomatic Huntington disease","volume":"72","author":"Kloppel","year":"2009","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01023-8_bib89","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.nbd.2011.03.018","article-title":"Natural history of disease in the YAC128 mouse reveals a discrete signature of pathology in Huntington disease","volume":"43","author":"Carroll","year":"2011","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-021-01023-8_bib90","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168556","article-title":"Correlations of behavioral deficits with brain pathology assessed through longitudinal MRI and histopathology in the HdhQ150\/Q150 mouse model of Huntington's disease","volume":"12","author":"Rattray","year":"2017","journal-title":"PLoS One"},{"key":"10.1007\/s13311-021-01023-8_bib91","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.neuroimage.2011.02.022","article-title":"Structural MRI detects progressive regional brain atrophy and neuroprotective effects in N171\u201382Q Huntington\u2019s disease mouse model","volume":"56","author":"Cheng","year":"2011","journal-title":"Neuroimage"},{"key":"10.1007\/s13311-021-01023-8_bib92","article-title":"Characterization of behavioral, neuropathological, brain metabolic and key molecular changes in zQ175 knock-in mouse model of Huntington's disease","volume":"11","author":"Peng","year":"2016","journal-title":"PLoS One"},{"key":"10.1007\/s13311-021-01023-8_bib93","doi-asserted-by":"crossref","first-page":"e50717","DOI":"10.1371\/journal.pone.0050717","article-title":"Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington's disease","volume":"7","author":"Heikkinen","year":"2012","journal-title":"PLoS One"},{"key":"10.1007\/s13311-021-01023-8_bib94","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/ana.25709","article-title":"Robust markers and sample sizes for multicenter trials of Huntington disease","volume":"87","author":"Wijeratne","year":"2020","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-021-01023-8_bib95","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S1474-4422(20)30143-5","article-title":"Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis","volume":"19","author":"Scahill","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-021-01023-8_bib96","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1001\/archneur.1996.00550120105023","article-title":"Basal ganglia volume and proximity to onset in presymptomatic Huntington disease","volume":"53","author":"Aylward","year":"1996","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-021-01023-8_bib97","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/jnnp.2007.128728","article-title":"Detection of Huntington's disease decades before diagnosis: the Predict-HD study","volume":"79","author":"Paulsen","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-021-01023-8_bib98","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.parkreldis.2019.02.004","article-title":"Combined cerebral atrophy score in Huntington's disease based on atlas-based MRI volumetry: sample size calculations for clinical trials","volume":"63","author":"Muller","year":"2019","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1007\/s13311-021-01023-8_bib99","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1474-4422(10)70276-3","article-title":"Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis","volume":"10","author":"Tabrizi","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-021-01023-8_bib100","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.neuroimage.2012.01.141","article-title":"Spatiotemporal mapping of brain atrophy in mouse models of Huntington's disease using longitudinal in vivo magnetic resonance imaging","volume":"60","author":"Aggarwal","year":"2012","journal-title":"Neuroimage"},{"key":"10.1007\/s13311-021-01023-8_bib101","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/hmg\/ddy061","article-title":"Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity and inhibits endoplasmic reticulum stress in a mouse model of Huntington's disease","volume":"27","author":"Zhou","year":"2018","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-021-01023-8_bib102","doi-asserted-by":"crossref","first-page":"31652","DOI":"10.1038\/srep31652","article-title":"Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease","volume":"6","author":"Garcia-Miralles","year":"2016","journal-title":"Sci Rep"},{"key":"10.1007\/s13311-021-01023-8_bib103","doi-asserted-by":"crossref","first-page":"101900","DOI":"10.1016\/j.nicl.2019.101900","article-title":"Specific patterns of brain alterations underlie distinct clinical profiles in Huntington's disease","volume":"23","author":"Garcia-Gorro","year":"2019","journal-title":"Neuroimage Clin"},{"key":"10.1007\/s13311-021-01023-8_bib104","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.nicl.2018.01.029","article-title":"Complex spatial and temporally defined myelin and axonal degeneration in Huntington disease","volume":"20","author":"Rosas","year":"2018","journal-title":"Neuroimage Clin"},{"key":"10.1007\/s13311-021-01023-8_bib105","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.nbd.2014.01.013","article-title":"White matter connectivity reflects clinical and cognitive status in Huntington's disease","volume":"65","author":"Poudel","year":"2014","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-021-01023-8_bib106","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/ana.410380602","article-title":"Selective neurodegeneration in Huntington's disease","volume":"38","author":"Albin","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-021-01023-8_bib107","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1523\/JNEUROSCI.0399-12.2013","article-title":"Oral administration of a small molecule targeted to block proNGF binding to p75 promotes myelin sparing and functional recovery after spinal cord injury","volume":"33","author":"Tep","year":"2013","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-021-01023-8_bib108","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1126\/science.1076595","article-title":"The neurotrophin receptor p75NTR as a positive modulator of myelination","volume":"298","author":"Cosgaya","year":"2002","journal-title":"Science"},{"key":"10.1007\/s13311-021-01023-8_bib109","doi-asserted-by":"crossref","unstructured":"Gonsalvez DG, Tran G, Fletcher JL, et al. A Brain-Derived Neurotrophic Factor-Based p75(NTR) Peptide Mimetic Ameliorates Experimental Autoimmune Neuritis Induced Axonal Pathology and Demyelination. eNeuro 2017;4.","DOI":"10.1523\/ENEURO.0142-17.2017"},{"key":"10.1007\/s13311-021-01023-8_bib110","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.neuroimage.2009.03.044","article-title":"In vivo evidence for the selective subcortical degeneration in Huntington's disease","volume":"46","author":"Douaud","year":"2009","journal-title":"Neuroimage"},{"key":"10.1007\/s13311-021-01023-8_bib111","first-page":"2621","article-title":"Structural and molecular myelination deficits occur prior to neuronal loss in the YAC128 and BACHD models of Huntington disease","volume":"25","author":"Teo","year":"2016","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-021-01023-8_bib112","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1002\/jnr.23965","article-title":"Brain diffusivity and structural changes in the R6\/2 mouse model of Huntington disease","volume":"95","author":"Vorisek","year":"2017","journal-title":"J Neurosci Res"},{"key":"10.1007\/s13311-021-01023-8_bib113","doi-asserted-by":"crossref","first-page":"e502","DOI":"10.1212\/NXI.0000000000000502","article-title":"Disruption of neurite morphology parallels MS progression","volume":"5","author":"Spano","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1007\/s13311-021-01023-8_bib114","doi-asserted-by":"crossref","unstructured":"Andica C, Kamagata K, Hatano T, et al. MR biomarkers of degenerative brain disorders derived from diffusion imaging. J Magn Reson Imaging 2019.","DOI":"10.1002\/jmri.27019"},{"key":"10.1007\/s13311-021-01023-8_bib115","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3389\/fnins.2019.00081","article-title":"Detecting microglial density with quantitative multi-compartment diffusion MRI","volume":"13","author":"Yi","year":"2019","journal-title":"Front Neurosci"},{"key":"10.1007\/s13311-021-01023-8_bib116","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1093\/cercor\/bhr360","article-title":"Multimodal MRI analysis of the corpus callosum reveals white matter differences in presymptomatic and early Huntington's disease","volume":"22","author":"Di Paola","year":"2012","journal-title":"Cereb Cortex"},{"key":"10.1007\/s13311-021-01023-8_bib117","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/mrm.27946","article-title":"Sensitivity of quantitative relaxometry and susceptibility mapping to microscopic iron distribution","volume":"83","author":"Colgan","year":"2020","journal-title":"Magn Reson Med"},{"key":"10.1007\/s13311-021-01023-8_bib118","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/77528","article-title":"Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease","volume":"6","author":"Chen","year":"2000","journal-title":"Nat Med"},{"key":"10.1007\/s13311-021-01023-8_bib119","doi-asserted-by":"crossref","first-page":"11840","DOI":"10.1073\/pnas.0502177102","article-title":"Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model","volume":"102","author":"Nguyen","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-021-01023-8_bib120","doi-asserted-by":"crossref","unstructured":"Cherny RA, Ayton S, Finkelstein DI, et al. PBT2 Reduces Toxicity in a C. elegans Model of polyQ Aggregation and Extends Lifespan, Reduces Striatal Atrophy and Improves Motor Performance in the R6\/2 Mouse Model of Huntington's Disease. J Huntingtons Dis 2012;1:211-219.","DOI":"10.3233\/JHD-120029"},{"key":"10.1007\/s13311-021-01023-8_bib121","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3233\/JHD-170273","article-title":"A critical evaluation of wet biomarkers for Huntington's disease: current status and ways forward","volume":"7","author":"Silajdzic","year":"2018","journal-title":"J Huntingtons Dis"},{"key":"10.1007\/s13311-021-01023-8_bib122","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3233\/JHD-130049","article-title":"A critical evaluation of inflammatory markers in Huntington's disease plasma","volume":"2","author":"Silajdzic","year":"2013","journal-title":"J Huntingtons Dis"},{"key":"10.1007\/s13311-021-01023-8_bib123","first-page":"936","article-title":"Immunomodulatory strategies for Huntington's disease treatment","volume":"16","author":"Colpo","year":"2017","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1007\/s13311-021-01023-8_bib124","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/978-1-4939-7825-0_17","article-title":"Biofluid biomarkers in Huntington's disease","volume":"1780","author":"Rodrigues","year":"2018","journal-title":"Methods Mol Biol"},{"key":"10.1007\/s13311-021-01023-8_bib125","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1097\/WNR.0b013e32832e34ee","article-title":"Distinct neuroinflammatory profile in post-mortem human Huntington's disease","volume":"20","author":"Silvestroni","year":"2009","journal-title":"Neuroreport"},{"key":"10.1007\/s13311-021-01023-8_bib126","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/mds.26950","article-title":"Disease stage and plasma levels of cytokines in Huntington's disease: a 2-year follow-up study","volume":"32","author":"Bouwens","year":"2017","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-021-01023-8_bib127","doi-asserted-by":"crossref","unstructured":"Wild E, Magnusson A, Lahiri N, et al. Abnormal peripheral chemokine profile in Huntington's disease. PLoS Curr 2011;3:RRN1231.","DOI":"10.1371\/currents.RRN1231"},{"key":"10.1007\/s13311-021-01023-8_bib128","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1084\/jem.20160776","article-title":"Potential biomarkers to follow the progression and treatment response of Huntington's disease","volume":"213","author":"Disatnik","year":"2016","journal-title":"J Exp Med"},{"key":"10.1007\/s13311-021-01023-8_bib129","first-page":"3144","article-title":"7,8-dihydroxyflavone ameliorates cognitive and motor deficits in a Huntington's disease mouse model through specific activation of the PLCgamma1 pathway","volume":"26","author":"Garcia-Diaz Barriga","year":"2017","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-021-01023-8_bib130","doi-asserted-by":"crossref","first-page":"5127","DOI":"10.1038\/s41598-017-05430-w","article-title":"Urinary extracellular domain of neurotrophin receptor p75 as a biomarker for amyotrophic lateral sclerosis in a Chinese cohort","volume":"7","author":"Jia","year":"2017","journal-title":"Sci Rep"},{"key":"10.1007\/s13311-021-01023-8_bib131","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11910-018-0890-y","article-title":"Novel imaging biomarkers for Huntington's disease and other hereditary choreas","volume":"18","author":"Fazio","year":"2018","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1007\/s13311-021-01023-8_bib132","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/mds.26118","article-title":"A longitudinal study of magnetic resonance spectroscopy Huntington's disease biomarkers","volume":"30","author":"Sturrock","year":"2015","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-021-01023-8_bib133","doi-asserted-by":"crossref","first-page":"16742","DOI":"10.1038\/s41598-017-17026-5","article-title":"Resting-state functional MRI reveals altered brain connectivity and its correlation with motor dysfunction in a mouse model of Huntington's disease","volume":"7","author":"Li","year":"2017","journal-title":"Sci Rep"},{"key":"10.1007\/s13311-021-01023-8_bib134","doi-asserted-by":"crossref","unstructured":"Pepin J, de Longprez L, Trovero F, et al. Complementarity of gluCEST and (1) H-MRS for the study of mouse models of Huntington's disease. NMR Biomed 2020:e4301.","DOI":"10.1002\/nbm.4301"},{"key":"10.1007\/s13311-021-01023-8_bib135","doi-asserted-by":"crossref","first-page":"e4007","DOI":"10.1002\/nbm.4007","article-title":"Connectomic imaging reveals Huntington-related pathological and pharmaceutical effects in a mouse model","volume":"31","author":"Chang","year":"2018","journal-title":"NMR Biomed"},{"key":"10.1007\/s13311-021-01023-8_bib136","doi-asserted-by":"crossref","unstructured":"Estevez-Fraga C, Scahill RI, Durr A, et al. Composite UHDRS Correlates With Progression of Imaging Biomarkers in Huntington's Disease. Mov Disord 2021.","DOI":"10.1002\/mds.28489"},{"key":"10.1007\/s13311-021-01023-8_bib137","doi-asserted-by":"crossref","first-page":"e49838","DOI":"10.1371\/journal.pone.0049838","article-title":"Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175","volume":"7","author":"Menalled","year":"2012","journal-title":"PLoS One"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01023-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-021-01023-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923011479?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923011479?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01023-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:52:31Z","timestamp":1761807151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923011479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":137,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S1878747923011479"],"URL":"https:\/\/doi.org\/10.1007\/s13311-021-01023-8","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuroimaging, Urinary, and Plasma Biomarkers of Treatment Response in Huntington's Disease: Preclinical Evidence with the p75NTR Ligand LM11A-31","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-021-01023-8","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 The authors. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}